A Phase 2/3 interventional study of Methylene blue infusion in Septic Shock and Hypoperfusion, sponsored by Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Methylene Blue in Shock, Septic — 2 open to participants now, 2 under way, 2 of them phase 3. Methylene Blue · Shock, Septic.
Among the 11 studies testing Methylene Blue in Shock, Septic, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 2/3, and was the 11th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →2 of the 11 studies testing Methylene Blue in Shock, Septic are open now, in 2 countries. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 0 days–28 days
By country, each count listing its studies:
Methylene Blue: first FDA approval 2016 (PROVAYBLUE), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 1
First in 2016; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 88 across the 11 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
1 of the studies testing Methylene Blue in Shock, Septic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264543Phase 3Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia IntensivaEarly Methylene Blue in the Microhemodynamics of Septic Patients | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing Methylene Blue in Shock, Septic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to evaluate the viability and feasibility of its protocol in order to conduct a larger clinical trial to assess whether methylene blue can improve patient-centered clinical outcomes such as mortality or length of hospital stay in septic shock patients.
One of the primary causes of high mortality in patients with septic shock is microcirculatory dysfunction related to vasodilation caused by excessive oxide nitric production. It has been shown that methylene blue, an old and safe drug that can reduce vasodilation by blocking nitric oxide pathways, is a vasopressor-sparing treatment in sepsis. Nevertheless, there is no evidence that methylene blue improves patient-centered clinical outcomes such as mortality. Understanding how early methylene blue affects the microhemodynamics of septic shock patients may lead to relevant clinical results that can improve their prognosis. So, the objective of the study is to evaluate the viability and feasibility of the study protocol for a larger clinical trial, assessing the effectiveness of early methylene blue in the microhemodynamics of septic shock patients, mainly through the capillary refill time measurement. For this purpose, a pilot study of an open-label, randomized, controlled and single-center clinical trial will be conducted, with two treatment arms: the intervention group (methylene blue plus standard treatment) and the control group (standard treatment). Fifty adult patients with septic shock within the first six hours of diagnosis will be included in this study. They will be randomized to either receive a methylene blue infusion or not. The randomization will be conducted using RedCap with a 1:1 ratio and variable block sizes. The primary outcome will be to assess the feasibility, which is defined as completing the study recruitment within the 12-month timeline and achieving protocol adherence of 90% or higher. Comparisons between groups for serially measured micro and macrohemodynamics parameters will be the secondary outcomes. Additionally, the incidence of adverse events related to methylene blue will be monitored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group will receive methylene blue plus standard treatment for septic shock, according to the international guidelines.
Drug: Methylene blue infusion
The control group will receive the standard treatment according to international guidelines for the management of sepsis and septic shock.
Methylene blue at a dose of 100mg (diluted in 100ml of 5% dextrose solution) in continuous infusion for 06 hours per day, for 03 days, plus standard treatment according to international guidelines for the management of sepsis and septic shock. The 03 consecutive MB infusions, each lasting 06 hours, will be performed every 24 hours, starting from randomization: the first infusion at T0, the second at T24, and the third at T48, considering T0 the moment after the patient randomization into the study. The interruption of the protocol will be recommended if vasopressors are completely discontinued during the three days of methylene blue infusion. The attending physician may discontinue methylene blue treatment if judges necessary. Similarly, interruption may occur if the family or patient request.
Also known as: Methylene blue, Phenothiazines
To evaluate the feasibility of the study protocol.
The primary outcome of the study is to evaluate feasibility, defined as completing the study protocol according to the planned timeline and with 90% or more protocol adherence. Protocol adherence will be defined as the use of the allocated therapy in the intervention group for 6 hours for 3 days (or interruption of methylene blue if the patient does not require a vasoactive drug anymore). Justified interruptions will not be considered violations.
Time frame: 28 days after randomization.
Capillary refill time
Serial capillary refill time from randomization up to 72 hours later.
Time frame: 72 hours after randomization.
Serum lactate level
Serial measurements of serum lactate level during the 72 hours after randomization.
Time frame: 72 hours after randomization.
Arteriovenous carbon dioxide difference (gapCO2)
Serial measurements of arteriovenous carbon dioxide difference (gapCO2) during 72h after randomization.
Time frame: 72h after randomization.
Central venous oxygen saturation (SvO2)
Serial measurements of central venous oxygen saturation (SvO2) during 72h after randomization.
Time frame: 72h after randomization.
Serial measurements of heart rate
Serial measurements of heart rate from randomization up to 72 hours later.
Time frame: 72 hours after randomization.
Serial measurements of mean arterial pressure
Serial measurements of mean arterial pressure from randomization up to 72 hours later.
Time frame: 72 hours after randomization.
Serial measurements of pulse pressure
Serial measurements of pulse pressure from randomization up to 72 hours later.
Time frame: 72 hours after randomization.
Serial measurements of systolic arterial pressure
Serial measurements of systolic arterial pressure from randomization up to 72 hours later.
Time frame: 72 hours after randomization.
Serial measurements of dyastolic arterial pressure
Serial measurements of dyastolic arterial pressure from randomization up to 72 hours later.
Time frame: 72 hours after randomization.
Methylene blue-related adverse events
Incidence of adverse events during the three days of administration of methylene blue and up to 28 days after.
Time frame: 28 days after randomization.
Variations in the Sequential Organ Failure Assessment-2 Score (SOFA-2)
Daily SOFA-2 score pontuatin from enrollment to 72 hours later. The SOFA score ranges from 0 to 24, being 24 the worst pontuation, indicating multiple organ dysfunction.
Time frame: From enrollment to 72 hours later.
Time to vasopressor discontinuation
Time to complete vasopressor discontinuation from the enrollment up to 28 days.
Time frame: 28 days after randomization.
Vasopressor dose (norepinephrine and vasopressin)
Vasopressor dose (norepinephrine and vasopressin) before and after the start of MB infusion, measuring before and after the methylene blue on the first, second, and third days of infusion.
Time frame: 72 hours after randomization.
Time to weaning from mechanical ventilation
Total number of days to wean from mechanical ventilation during the 28 days after randomization.
Time frame: 28 days after randomization.
Need for renal replacement therapy (RRT)
Total number of days of renal replacement therapy (RRT) during 28 days after randomization.
Time frame: 28 days after randomization.
Intensive care unit length of stay
Total number of days until intensive care unit discharge.
Time frame: 28 days after randomization.
28-day mortality
All-cause mortality at day 28 after randomization.
Time frame: 28 days after randomization.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.
Of 13 phase 2/3 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylene Blue
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva